High-<i>b-</i>Value Diffusion-weighted MR Imaging for Pretreatment Prediction and Early Monitoring of Tumor Response to Therapy in Mice

Roth, Yiftach; Tichler, Thomas; Kostenich, Genady; Ruíz-Cabello, Jesús; Maier, Stephan E.; Cohen, Jack S.; Orenstein, Arie; Mardor, Yael

doi:10.1148/radiol.2322030778

Cited by 155 publications

(116 citation statements)

References 26 publications

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…12,13 Although the mechanism of rise in the ADC at an early phase of treatment following cytotoxic and radiation treatment in experimental and human tumors is not fully understood, it has been speculated that a rise in ADC might be attributed to an increase in the fractional volume and diffusion of water molecules in the extracellular space that occurs with the disorganized micro- structure in necrosis and apoptosis in response to treatment.…”

Section: Discussionmentioning

confidence: 99%

Fractional Change in Apparent Diffusion Coefficient as an Imaging Biomarker for Predicting Treatment Response in Head and Neck Cancer Treated with Chemoradiotherapy

Matoba

Tuji

Shimode

et al. 2013

American Journal of Neuroradiology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Fractional Change in Apparent Diffusion Coefficient as an Imaging Biomarker for Predicting Treatment Response in Head and Neck Cancer Treated with Chemoradiotherapy

Matoba

Tuji

Shimode

et al. 2013

American Journal of Neuroradiology

View full text Add to dashboard Cite

show abstract

“…Higher b-values may provide better characterisation of PC and treatment response in experimental mouse models [55]. Larger b-values are necessary to limit the effects of bulk motion (perfusion) [56].…”

Section: B-valuementioning

confidence: 99%

Diffusion weighted imaging in prostate cancer

2010

View full text Add to dashboard Cite

Diffusion-weighted imaging has generated substantial interest in the hope that it can be developed into a robust technique to improve the accuracy of MRI for the evaluation of prostate cancer. This technique has the advantages of short acquisition times, no need for intravenous administration of contrast medium, and the ability to study diffusion of water molecules that indirectly reflects tissue cellularity. In this article, we review the existing literature on the utility of DWI in tumour detection, localisation, treatment response, limitations of the technique, how it compares with other imaging techniques, technical considerations and future directions.

show abstract

“…87 Baseline ADC values may predict the likelihood that a patient will respond to therapy. 88,89 For example, a significantly higher ADC value at baseline has been reported for nonresponding patients with rectal adenocarcinomas compared with the value for patients who responded to chemotherapy and chemoradiation. 89 However, the prognostic implications of the pretreatment ADC values Original Article require further validation.…”

Section: Diffusion-weighted Imagingmentioning

confidence: 99%

“…90 An increase in ADC values as a result of therapyinduced tumor cell lysis and necrosis has been demonstrated in both preclinical and clinical studies. 88 Changes in ADC values may precede those in tumor volume, making DWI a potential biomarker for early response to therapy. Furthermore, several studies have demonstrated a positive association between therapy-induced elevation in ADC values and better clinical outcomes to a variety of antitumor therapies.…”

Section: Diffusion-weighted Imagingmentioning

confidence: 99%

Magnetic resonance imaging as a biomarker in renal cell carcinoma

Pedrosa

Alsop

Rofsky

2009

Cancer

View full text Add to dashboard Cite

The ability to noninvasively discriminate the most common types of renal cell carcinoma (RCC) based on their magnetic resonance imaging (MRI) appearances or their magnetic resonance phenotypes is achievable. Intracellular lipids, a histologic characteristic of the clear cell RCC, can be identified on chemical shift MRI. Intratumoral hemosiderin deposition, as observed histologically with papillary RCC, correlates to the low signal intensity on T2-weighted images. In addition to morphologic imaging features, the different subtypes of RCC have distinct patterns of enhancement on dynamic contrast-enhanced MRI. Clear cell tumors demonstrate much greater enhancement than papillary and chromophobe RCCs during the corticomedullary and nephrographic phases. The MRI technique arterial spin labeling (ASL) uses magnetic fields to label the water protons in arterial blood and measures blood flow into tissue; quantitative images of blood flow can be generated without exogenous contrast media. Multiple measurements of tumor perfusion may be repeated before and after a physiologic or drug challenge (ie, antiangiogenic therapy). In RCC xenografts and in patients with metastatic RCC, ASL MRI assessments can be used to monitor blood flow changes in response to antiangiogenic therapies. High blood flow on ASL MRI in RCC xenografts correlates with viable tumor at histopathologic analysis, whereas zones of absent or diminished signal correspond to necrosis. ASL MRI has the potential to serve as a biomarker for patients with metastatic RCC by offering a noninvasive measure of tumor blood flow changes accompanying antiangiogenic therapy. Cancer 2009;115(10 suppl):2334-45.

show abstract

High-b-Value Diffusion-weighted MR Imaging for Pretreatment Prediction and Early Monitoring of Tumor Response to Therapy in Mice

Abstract: High-b-value diffusion-weighted MR imaging has potential use for the early detection of response to therapy and for predicting treatment outcome prior to initiation of chemotherapy.

Cited by 155 publications

References 26 publications

Fractional Change in Apparent Diffusion Coefficient as an Imaging Biomarker for Predicting Treatment Response in Head and Neck Cancer Treated with Chemoradiotherapy

Fractional Change in Apparent Diffusion Coefficient as an Imaging Biomarker for Predicting Treatment Response in Head and Neck Cancer Treated with Chemoradiotherapy

Diffusion weighted imaging in prostate cancer

Magnetic resonance imaging as a biomarker in renal cell carcinoma

Contact Info

Product

Resources

About